Pitavastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

Cardiology in Review

Volumn 18, Issue 5, 2010, Pages 264-267

  Ahmad, Haniyyah ^a   Cheng Lai, Angela ^a  

^a Jack D Weiler Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATAZANAVIR; ATORVASTATIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OROSOMUCOID; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; RITONAVIR; SIMVASTATIN; THROMBOXANE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ARTHRALGIA; ATHEROSCLEROSIS; BACKACHE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DYSLIPIDEMIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLUENZA; INHIBITION KINETICS; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PROTEIN SYNTHESIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SMOOTH MUSCLE FIBER;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG INTERACTIONS; HUMANS; HYPERCHOLESTEROLEMIA; QUINOLINES; RISK FACTORS;

EID: 77955779222     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181ebdb2f     Document Type: Review

References (19)

1. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: comparison with atorvastatin. Circ J. 2009;73:1466-1472.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
6. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
7. Members of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Study Group. Rosuv-astatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
8. Furberg CD. Natural statins and stroke risk. Circulation. 1999;99:185-188.
9. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59: 239-252.
10. Product Information: LIVALO (pitavastatin) Tablet, Oral Film Coated. Cin-cinatti, OH: Kowa Pharmaceuticals; 2009.
11. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2009;54:293-302.
12. Nomura S. Pitavastatin in the management of hypercholesterolemia. Clin Med: Ther. 2009;1:1477-1488.
13. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reduc-tase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138-144.
14. Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res. 2002;25:279-285.
15. Igel M, Sudhop T, Von Bergmann K. Pharmacology of 3-hydroxy-3-meth- ylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002;42:835-845.
16. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs. 2000;9:2653-2661.
17. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation. 2004;110:1061-1068.
18. Sansanayudh N. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Pharmacotherapy. 2010;44:415-423.
19. Watson KE. Pitavastatin: the newest HMG-CoA reductase inhibitor. Rev Cardiovasc Med. 2010;11:26-32.